Logo image of AURA

AURA BIOSCIENCES INC (AURA) Stock Fundamental Analysis

USA - NASDAQ:AURA - US05153U1079 - Common Stock

6.08 USD
-0.06 (-0.98%)
Last: 10/30/2025, 8:00:01 PM
6.08 USD
0 (0%)
After Hours: 10/30/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AURA. AURA was compared to 534 industry peers in the Biotechnology industry. While AURA has a great health rating, there are worries on its profitability. AURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AURA has reported negative net income.
In the past year AURA has reported a negative cash flow from operations.
In the past 5 years AURA always reported negative net income.
In the past 5 years AURA always reported negative operating cash flow.
AURA Yearly Net Income VS EBIT VS OCF VS FCFAURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -49.60%, AURA perfoms like the industry average, outperforming 50.56% of the companies in the same industry.
AURA has a better Return On Equity (-58.05%) than 62.73% of its industry peers.
Industry RankSector Rank
ROA -49.6%
ROE -58.05%
ROIC N/A
ROA(3y)-34.61%
ROA(5y)-53.81%
ROE(3y)-40.36%
ROE(5y)-61.34%
ROIC(3y)N/A
ROIC(5y)N/A
AURA Yearly ROA, ROE, ROICAURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AURA Yearly Profit, Operating, Gross MarginsAURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, AURA has more shares outstanding
AURA has more shares outstanding than it did 5 years ago.
AURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AURA Yearly Shares OutstandingAURA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AURA Yearly Total Debt VS Total AssetsAURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 3.99 indicates that AURA is not in any danger for bankruptcy at the moment.
AURA's Altman-Z score of 3.99 is fine compared to the rest of the industry. AURA outperforms 71.35% of its industry peers.
There is no outstanding debt for AURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.99
ROIC/WACCN/A
WACCN/A
AURA Yearly LT Debt VS Equity VS FCFAURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 12.39 indicates that AURA has no problem at all paying its short term obligations.
AURA has a Current ratio of 12.39. This is amongst the best in the industry. AURA outperforms 85.58% of its industry peers.
AURA has a Quick Ratio of 12.39. This indicates that AURA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.39, AURA belongs to the top of the industry, outperforming 85.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.39
Quick Ratio 12.39
AURA Yearly Current Assets VS Current LiabilitesAURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.62% over the past year.
EPS 1Y (TTM)11.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AURA will show a decrease in Earnings Per Share. The EPS will decrease by -2.69% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.11%
EPS Next 2Y-9.61%
EPS Next 3Y-2.69%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AURA Yearly Revenue VS EstimatesAURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
AURA Yearly EPS VS EstimatesAURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AURA. In the last year negative earnings were reported.
Also next year AURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AURA Price Earnings VS Forward Price EarningsAURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AURA Per share dataAURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

AURA's earnings are expected to decrease with -2.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.61%
EPS Next 3Y-2.69%

More info and screens

0

5. Dividend

5.1 Amount

AURA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURA BIOSCIENCES INC

NASDAQ:AURA (10/30/2025, 8:00:01 PM)

After market: 6.08 0 (0%)

6.08

-0.06 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-06 2025-11-06/amc
Inst Owners76.37%
Inst Owner Change0.15%
Ins Owners2.07%
Ins Owner Change13.02%
Market Cap377.69M
Revenue(TTM)N/A
Net Income(TTM)-101378000
Analysts83.33
Price Target21.17 (248.19%)
Short Float %5.64%
Short Ratio12.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.25%
Min EPS beat(2)-9.78%
Max EPS beat(2)-0.72%
EPS beat(4)1
Avg EPS beat(4)-4.73%
Min EPS beat(4)-14.95%
Max EPS beat(4)6.54%
EPS beat(8)4
Avg EPS beat(8)-1.55%
EPS beat(12)6
Avg EPS beat(12)0.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.12%
PT rev (3m)-3.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 2.16
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.6%
ROE -58.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.61%
ROA(5y)-53.81%
ROE(3y)-40.36%
ROE(5y)-61.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.39
Quick Ratio 12.39
Altman-Z 3.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)83.19%
Cap/Depr(5y)119.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-21.11%
EPS Next 2Y-9.61%
EPS Next 3Y-2.69%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.32%
OCF growth 3YN/A
OCF growth 5YN/A

AURA BIOSCIENCES INC / AURA FAQ

Can you provide the ChartMill fundamental rating for AURA BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to AURA.


What is the valuation status of AURA BIOSCIENCES INC (AURA) stock?

ChartMill assigns a valuation rating of 0 / 10 to AURA BIOSCIENCES INC (AURA). This can be considered as Overvalued.


Can you provide the profitability details for AURA BIOSCIENCES INC?

AURA BIOSCIENCES INC (AURA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for AURA BIOSCIENCES INC?

The Earnings per Share (EPS) of AURA BIOSCIENCES INC (AURA) is expected to decline by -21.11% in the next year.